Skip to main content
Log in

Is it important to identify extended-spectrum beta-lactamase-producing isolates?

  • Editorial
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Jacoby GA, Medeiros AA: More extended-spectrum β-lactamases. Antimicrobial Agents and Chemotherapy 1991, 35: 1697–1704.

    PubMed  Google Scholar 

  2. Bush K, Jacoby GA, Medeiros AA: A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrobial Agents and Chemotherapy 1995, 39: 1211–1233.

    PubMed  Google Scholar 

  3. Shannon KP, King A, Phillips I, Nicholas MH, Philippon A: Importation of organisms producing broad-spectrum SHV-group β-lactamases into the United Kingdom. Journal of Antimicrobial Chemotherapy 1990, 25: 343–351.

    PubMed  Google Scholar 

  4. Katsanis GP, Spargo J, Ferraro MJ, Sutton L, Jacoby GA: Detection ofKlebsiella pneumoniae andEscherichia coli strains producing extended-spectrum β-lactamases. Journal of Clinical Microbiology 1994, 32: 691–696.

    PubMed  Google Scholar 

  5. Kliebe C, Nies BA, Meyer JF, Tolxdorff-Neutzling RM, Wiedemann B: Evolution of plasmid-coded resistance to broad spectrum cephalosporins. Antimicrobial Agents and Chemotherapy 1985, 28: 302–307.

    PubMed  Google Scholar 

  6. Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S: Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates ofKlebsiella pneumoniae andSerratia marcescens. Infection 1983, 11: 315–317.

    PubMed  Google Scholar 

  7. Petit A, Sirot DL, Chanal CM, Sirot JL, Labia R, Gerbaud G, Cluzel RA: Novel plasmid-mediated β-lactamase in clinical isolates ofKlebsiella pneumoniae more resistant to ceftazidime than to other broad-spectrum cephalosporins. Antimicrobial Agents and Chemotherapy 1988, 32: 626–630.

    PubMed  Google Scholar 

  8. Sirot D, Sirot J, Labia R, Morand A, Courvalin P, Darfeuille-Michaud A, Perroux R, Cluzel R: Transferable resistance to third-generation cephalosporins in clinical isolates ofKlebsiella pneumoniae: identification of CTX-1, a novel β-lactamase. Journal of Antimicrobial Chemotherapy 1987, 20: 323–334.

    PubMed  Google Scholar 

  9. Kitzis MD, Billot-Klein D, Goldstein FW, Williamson R, Nhieu GTV, Carlet J, Acar JF, Gutmann L: Dissemination of the novel plasmid-mediated β-lactamase CTX-1, which confers resistance to broad spectrum cephalosporins, and its inhibition by β-lactamase inhibitors. Antimicrobial Agents and Chemotherapy 1988, 32: 9–14.

    PubMed  Google Scholar 

  10. Bauernfeind A, Hörl G: Novel R-factor borne β-lactamase ofEscherichia coli conferring resistance to cephalosporins. Infection 1987, 15: 257–259.

    PubMed  Google Scholar 

  11. Spencer RC, Wheat PF, Winstanley TG, Cox DM, Plested SJ: Novel β-lactamase in a clinical isolate ofKlebsiella pneumoniae conferring unusual resistance to β-lactam antibiotics. Journal of Antimicrobial Chemotherapy 1987, 20: 919–921.

    PubMed  Google Scholar 

  12. Rice LB, Willey SH, Papanicolaou GA, Medeiros AA, Eliopoulos GM, Moellering RC Jr, Jacoby GA: Outbreak of ceftazidime resistance caused by extended-spectrum β-lactamases at a Massachusetts chronic-care facility. Antimicrobial Agents and Chemotherapy 1990, 34: 2193–2199.

    PubMed  Google Scholar 

  13. Meyers KS, Urban C, Eagan JA, Berger BJ, Rahal JJ: Nosocomial outbreak ofKlebsiella infection resistant to late-generation cephalosporins. Annals of Internal Medicine 1993, 119: 353–358.

    PubMed  Google Scholar 

  14. Sirot DL, Goldstein FW, Soussy CJ, Courtieu AL, Husson MO, Lemozy L, Morel MMC, Perez R, Quentin-Noury C, Reverdy ME, Scheftel JM, Rosenbaum M, Rezvani Y: Resistance to cefotaxime and seven other β-lactams in members of the familyEnterobacteriaceae: a 3 year survey in France. Antimicrobial Agents and Chemotherapy 1992, 36: 1677–1681.

    PubMed  Google Scholar 

  15. Sirot D, Champs CD, Chanal C, Labia R, Darfeuille-Michaud A, Perrous R, Sirot J: Translocation of antibiotic resistance determinants including an extended-spectrum β-lactamase between conjugative plasmids ofKlebsiella pneumoniae andEscherichia coli. Antimicrobial Agents and Chemotherapy 1991, 35: 1576–1581.

    PubMed  Google Scholar 

  16. Bradford P, Cherubin CE, Idemyor V, Rasmussen BA, Bush K: Multiply resistantKlebsiella pneumoniae from two Chicago hospitals: identification of the extended spectrum TEM-12 and TEM-10 ceftazidime-hydrolyzing β-lactamases in a single isolate. Antimicrobial Agents and Chemotherapy 1994, 38: 761–766.

    PubMed  Google Scholar 

  17. Pangon B, Bizet C, Buré A, Pichon F, Philippon A, Regnier B, Gutmann L: In vivo selection of a cephamycin-resistant, porin-deficient mutant ofKlebsiella pneumoniae producing a TEM-3 β-lactamase. Journal of Infectious Diseases 1989, 159: 1005–1006.

    PubMed  Google Scholar 

  18. Martinez-Martínez L, Hernández-Allés S, Alberti S, Tomás JM, Benedi V, Jacoby GA: In vivo selection of porin-deficient mutants ofKlebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum cephalosporins. Antimicrobial Agents and Chemotherapy 1996, 40: 342–348.

    PubMed  Google Scholar 

  19. Petit A, Gerbaud G, Sirot D, Courvalin P, Sirot J: Molecular epidemiology of TEM-3 (CTX-1) β-lactamase. Antimicrobial Agents and Chemotherapy 1990, 34: 219–224.

    PubMed  Google Scholar 

  20. Rasmussen BA, Bradford PA, Quinn JP, Wiener J, Weinstein RA, Bush K: Genetically diverse ceftazidime resistant isolates from a single center: biochemical and genetic characterization of TEM-10 β-lactamases encoded by different nucleotide sequences. Antimicrobial Agents and Chemotherapy 1993, 37: 1989–1992.

    PubMed  Google Scholar 

  21. Naumovski L, Quinn JP, Miyashiro D, Patel M, Bush K, Singer SB, Graves D, Palzkill T, Arvin AM: Outbreak of ceftazidime resistance due to a novel extended-spectrum β-lactamase in isolates from cancer patients. Antimicrobial Agents and Chemotherapy 1992, 36: 1991–1996.

    PubMed  Google Scholar 

  22. Bradford PA, Urban C, Jaiswal A, Mariano N, Rasmussen BA, Projan SJ, Rahal JJ, Bush K: SHV-7, a novel cefotaxime-hydrolyzing β-lactamase, identified inEscherichia coli isolates from hospitalized nursing home patients. Antimicrobial Agents and Chemotherapy 1995, 39: 899–905.

    PubMed  Google Scholar 

  23. Quinn JR Miyashiro D, Sahm D, Flamm R, Bush K: Novel plasmid-mediated β-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates ofKlebsiella pneumoniae. Antimicrobial Agents and Chemotherapy 1989, 33: 1451–1456.

    PubMed  Google Scholar 

  24. Weber DA, Sanders CC, Bakken JS, Quinn JP: A novel chromosomal TEM derivative and alterations in outer membrane proteins together mediate selective ceftazidime resistance inEscherichia coli. Journal of Infectious Diseases 1990, 162: 460–465.

    PubMed  Google Scholar 

  25. Urban CM, Meyer KS, Mariano N, Rahal JJ, Flamm R, Rasmussen BA, Bush K: Identification of TEM-26 β-lactamase responsible for a major outbreak of ceftazidime resistantKlebsiella pneumoniae. Antimicrobial Agents and Chemotherapy 1994, 38: 392–395.

    PubMed  Google Scholar 

  26. Jarlier V, Nicolas M, Fournier G, Philippon A: Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents inEnterobacteriaceae: hospital prevalence and susceptibility patterns. Reviews of Infectious Diseases 1988, 10: 867–878.

    PubMed  Google Scholar 

  27. Thomson KS, Sanders CC, Washington JA II: High-level resistance to cefotaxime and ceftazidime inKlebsiella pneumoniae isolates from Cleveland, Ohio. Antimicrobial Agents and Chemotherapy 1991, 35: 1001–1003.

    PubMed  Google Scholar 

  28. Thomson KS, Sanders CC: Detection of extended-spectrum β-lactamases in members of the familyEnterobacteriaceae: comparison of the double-disk and three-dimensional tests. Antimicrobial Agents and Chemotherapy 1992, 36: 1877–1882.

    PubMed  Google Scholar 

  29. Baquero F, Cantón R, Martinez-Beltrán J, Bolström A: The E-test as an epidemiological tool. Diagnostic Microbiology and Infectious Diseases 1992, 15: 483–487.

    Google Scholar 

  30. Sanchez ML, Barrtee MS, Jones RN: The E-test applied to susceptibility tests of gonococci, multiply-resistant enterococci andEnterobacteriaceae producing potent β-lactamases. Diagnostic Microbiology and Infectious Disease 1992, 15: 459–463.

    PubMed  Google Scholar 

  31. Nüesch-Inderbinen MT, Hächler H, Kayser FH: Detection of extended-spectrum SHV β-lactamases in clinical isolates by a precise molecular genetic method and comparison with the E test ESBL. European Journal of Clinical Microbiology and Infectious Diseases 1996, 15: 398–402.

    Google Scholar 

  32. Podbielski A, Schönling J, Melzer B, Haase G: Different promoters of SHV-2 and SHV-2a β-lactamase lead to diverse levels of cefotaxime resistance in their bacterial producers. Journal of General Microbiology 1991, 137: 1667–1675.

    PubMed  Google Scholar 

  33. Nüesch-Inderbinen MT, Hächler H, Kayser FH: New system based on site-directed mutagenesis for highly accurate comparison of resistance levels conferred by SHV β-lactamases. Antimicrobial Agents and Chemotherapy 1995, 39: 1726–1730.

    PubMed  Google Scholar 

  34. Garbarg-Chenon A, Godard V, Labia R, Nicolas J-C: Nucleotide sequence of SHV-2 β-lactamase gene. Antimicrobial Agents and Chemotherapy 1990, 34: 1444–1446.

    PubMed  Google Scholar 

  35. Sowek JA, Singer SB, Ohringer S, Malley MF, Dougherty TJ, Gougoutas JZ, Bush K: Substitution of lysine at position 104 or 240 of TEM-1pTZ18R β-lactamase enhances the effect of serine-164 substitution on the hydrolysis or affinity for cephalosporins and the monobactam aztreonam. Biochemistry 1991, 30: 3179–3188.

    PubMed  Google Scholar 

  36. Rice LB, Yao JDC, Klimm K, Eliopoulos GM, Moellering RC Jr: Efficacy of different β-lactams against an extended-spectrum β-lactamase-producingKlebsiella pneumoniae strain in the rat intra-abdominal abscess model. Antimicrobial Agents and Chemotherapy 1991, 35: 1243–1244.

    PubMed  Google Scholar 

  37. Jett BD, Ritchie DJ, Reichley R, Bailey TC, Sahm DF: Susceptibility of ESBL-producing organisms. Antimicrobial Agents and Chemotherapy 1995, 39: 1187–1190.

    PubMed  Google Scholar 

  38. Knox JR: Extended-spectrum and inhibitor-resistant TEM-type β-lactamase: mutations, specificity and three-dimensional structure. Antimicrobial Agents and Chemotherapy 1995, 39: 2593–2601.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bush, K. Is it important to identify extended-spectrum beta-lactamase-producing isolates?. Eur. J. Clin. Microbiol. Infect. Dis. 15, 361–364 (1996). https://doi.org/10.1007/BF01690090

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01690090

Navigation